In a short, simple securities filing on Monday, GlaxoSmithKline confirmed that its new head of pharmaceuticals will start pn Sept. 4.
He’s Luke Miels, whom GSK poached from rival AstraZeneca.
AstraZenea fought the move by its European business leader, but new GSK CEO Emma Walmsley prevailed in the legal tussle to land a top lieutenant.
The filing reads:
GSK confirms start date for Luke Miels
GSK has reached an agreement with AstraZeneca that Luke Miels will commence his appointment as President, Global Pharmaceuticals, GSK on 4 September 2017.
No terms of the settlement were disclosed.
AstraZeneca had filed suit to block the move on May 16.
“For Walmsley, his appointment is viewed as pivotal, since he will be a key lieutenant as she tries to steer GSK’s core pharmaceuticals business towards improved productivity and higher profits,” The New York Times reports.
Abbas Hussain is leaving the GSK pharma position.
Miels has also worked at Roche and Sanofi.
GSK maintains a campus in RTP and a manufacturing plant in Zebulon, employing several thousand people across the Triangle.
